NEW YORK, NY / ACCESSWIRE / May 27, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
NEW YORK, NY / ACCESSWIRE / May 26, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020. If you are a shareholder who suffered a loss, click here to participate.
NEW YORK, NY / ACCESSWIRE / May 25, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020. If you are a shareholder who suffered a loss, click here to participate.
Los Angeles, California--(Newsfile Corp. - May 27, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ...
NEW YORK, NY / ACCESSWIRE / May 27, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. A class action has commenced on behalf of certain shareholders in VMware, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) VMware's reporting with respect to its backlog of unfilled orders was not in compliance with all relevant accounting and disclosure requirements; (ii) the foregoing subjected the Company to a foreseeable risk of heightened regulatory scrutiny and/or investigation; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Robbins Geller Rudman & Dowd LLP announces that purchasers of Gossamer Bio, Inc. (NASDAQ:GOSS) common stock between February 8, 2019 and December 13, 2019 (the "Class Period"), including acquirers of Gossamer stock pursuant to the Company’s February 8, 2019 initial public offering ("IPO"), have until June 2, 2020 to seek appointment as lead plaintiff in a securities class action lawsuit. The case is captioned Kuhne v. Gossamer Bio, Inc., No. 20-cv-00649 (S.D. Cal.), and is assigned to Judge Dana M. Sabraw. The Gossamer Bio securities class action lawsuit charges Gossamer, certain of its officers and directors, and the underwriters of its IPO with violations of the Securities Exchange Act of 1934 and/or the Securities Act of 1933.
NEW YORK, NY / ACCESSWIRE / May 24, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
NEW YORK, NY / ACCESSWIRE / May 26, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
New York, New York--(Newsfile Corp. - May 27, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in connection with its February ...
LOS ANGELES, CA / ACCESSWIRE / May 22, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Gossamer Bio, Inc. ("Gossamer" ...
Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020. If you are a shareholder who suffered a loss, click here to participate.
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (GOSS) (1) pursuant and/or traceable to the Company’s initial public offering in February 2019 (the "IPO" or "Offering"); and/or (2) between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/goss.
Shareholder rights law firm Robbins LLP announces that a purchaser of Gossamer Bio, Inc. (NASDAQ: GOSS) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 8, 2019 and December 13, 2019, as well as violations of the Securities Act of 1933 pursuant to its February 2019 initial public offering ("IPO"). Gossamer is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapeutics. Gossamer's leading product is GB001, a DP2 antagonist drug for the treatment of asthma.
NEW YORK, NY / ACCESSWIRE / May 22, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
New York, New York--(Newsfile Corp. - May 27, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in ...
Aerpio Pharmaceuticals, Inc. (“Aerpio”) (ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement has been reached to evaluate razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. Approximately 10-15% of those infected with the highly contagious SARS-CoV2 virus, the cause of COVID-19, develop ARDS with a death rate in the 2-10% range. Preclinical models, large human observational studies, and human genetic studies from leading groups worldwide have independently arrived at the concept that a vascular endothelial receptor, Tie2, may play a pivotal role in the defense against microvascular breach in acute respiratory distress syndrome (ARDS) 1-4.
Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (GOSS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, NY / ACCESSWIRE / May 25, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...